Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors ...

New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...

The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

US FDA grants fast track designation to DualityBio's next-generation HER3 ADC DB-1310 to treat nonsquamous non-small cell lung cancer: Shanghai Wednesday, July 23, 2025, 14:30 Hrs ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced it expects topline data in early 2026 from its global Phase 3 FURVENT trial ...

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

The abstracts accepted for mini oral presentations include updated efficacy and safety data from the Phase 2b REZILIENT1 ...

DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with new long-term overall survival (OS) ...

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent ...

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.